After ten days the carcinogenesis is promoted by Fe-NTA at a dose level of 9 mg Fe/kg body weight (ip) twice a week for 24 weeks.
The A models always provided a better description of the data than their respective parent CA or IA models, while there were no significant improvements by using models explaining a dose level dependent antagonism (DL).
Dipterex was teratogenic after administration by gavage (t.i.d). at a dose level of 480 mg/kg-day to the CP rat on days 6 through 15 of gestation, but not when administered only on days 8 or 10 of gestation.
Group II received a single intraperitoneal injection of DEN at a dose level of 200 mg/kg body weight in the first day and after ten days the carcinogenesis was promoted by Fe NTA at a dose level of 9 mg Fe/kg body weight (ip) twice a week for twenty-four weeks.
While body weight for female animals was unaffected by treatment at either cyclosporin A dose levels, that of male animals was significantly decreased in the low dose group at day 28 (−15%), and throughout the study for the high dose group (−13% on day 28).
Creatinine clearance values ≥60 mL/min required no dose modification, 50 59 mL/min required a reduction in both S-1 and CDDP by one dose level, 40 49 mL/min required a reduction of both S-1 and CDDP by two dose levels, and those <40 mL/min required the cessation of both S-1 and CDDP.
There was a statistically significant decrease in Css,min between Cycle 1 and Cycle 2 (P=0.004), but no difference within a cycle or by dose level (P>0.05).
If a DLT resulted from a nonhaematological toxicity, the next DHA paclitaxel dose treatment was reduced by one dose level.
If a patient encountered DLT, the dose of XR11576 was decreased by one dose level at re-treatment.
The irinotecan dose was reduced by one dose level (10 mg m−2) for all subsequent treatment courses if a patient experienced grade 4 neutropenia, grade 3 thrombocytopenia, or grade 3 nonhaematologic toxicity in the previous treatment cycle.
